SCHEDULE 13D/A 1376474-24-000516 0002020621 XXXXXXXX LIVE 8 Common Stock, par value $0.00001 per share 12/26/2025 true 0001808377 45791D109 Innovative Eyewear Inc

11900 BISCAYNE BLVD STE 630 MIAMI FL 33181

Vladimir Galkin (310) 880-6330 10900 NW 97th Street, #102 Miami FL 33178 0002020621 Galkin Vladimir b PF X1 0 796007 0 796007 796007 16.0 IN (1) The shares of Common Stock are held jointly by Vladimir Galkin and Angelica Galkin, husband and wife. Vladimir Galkin and Angelica Galkin have shared voting power and dispositive power over 796,007 shares of Common Stock. (2) Based on 5,350,183 shares of the Issuer's common stock issued and outstanding as of November 6, 2025, based on information reported by the Issuer in the Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, and filed with the Securities and Exchange Commission (the SEC) on November 13, 2025. 0002038764 Galkin Angelica b PF X1 0 796007 0 796007 796007 16.0 IN (1) The shares of Common Stock are held jointly by Vladimir Galkin and Angelica Galkin, husband and wife. Vladimir Galkin and Angelica Galkin have shared voting power and dispositive power over 796,007 shares of Common Stock. (2) Based on 5,350,183 shares of the Issuer's common stock issued and outstanding as of November 6, 2025, based on information reported by the Issuer in the Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, and filed with the Securities and Exchange Commission (the SEC) on November 13, 2025. Common Stock, par value $0.00001 per share Innovative Eyewear Inc 11900 BISCAYNE BLVD STE 630 MIAMI FL 33181 This Amendment No. 8 amends the Schedule 13D filed on September 23, 2024 (the "Original Schedule 13D" and, as amended by Amendment No. 1 to Schedule 13D filed on September 23, 2024, and as amended by Amendment No.2 to Schedule 13D filed on September 23, 2024 , and as amended by Amendment No. 3 filed on September 23, 2024, and as amended by Amendment No. 4 filed on September 24, 2024, and as amended by Amendment No. 5 filed on September 25, 2024, and as amended by Amendment No. 6 filed on October 4, 2024, and as amended by Amendment No. 7 filed on December 12, 2025, as amended the "Schedule 13D"). This statement of beneficial ownership on Schedule 13D is jointly filed by each of Vladimir Galkin and Angelica Galkin, husband and wife (collectively, the "Reporting Persons" and individually, a "Reporting Person"), with respect to the shares of the common stock, par value $0.00001 per share (the " Common Stock"), of Innovative Eyewear, Inc., a Florida corporation (the " Issuer"). According to the Issuer, the address of its principal executive office is 1900 Biscayne Blvd., Suite 630, North Miami, Florida 33181. Unless specifically amended hereby, the disclosures set forth in the Original Schedule 13D remain unchanged. Capitalized terms used but not otherwise defined herein have the meanings given to them in the Original Schedule 13D filed on September 23, 2024. Effective December 26, 2025, the Reporting Persons sold approximately 2.7% of the Issuer's outstanding Common Stock through open market transactions, since their filing of Amendment No. 7 to this Schedule 13D filed on December 12, 2025. The Reporting Persons no longer believe that the Issuer represents an attractive investment based on the Issuer's business prospects and strategy, and intend to divest of their remaining shares of Common Stock in open market transactions over the next six (6) months. The Reporting Persons do not expect to have further communications with the board of directors of the Issuer, members of management and/or other shareholders with respect to operational, strategic, financial or governance matters. This represents a change in purpose from the initial investment. Notwithstanding the foregoing, the Reporting Persons reserve the right to acquire, or cause to be acquired, additional securities of the Issuer, to dispose of, or cause to be disposed of, such securities at any time or to formulate other purposes, plans or proposals regarding the Issuer or any of its securities, to the extent deemed advisable in light of general investment and trading policies of the Reporting Persons, market conditions or other factors. Other than as set forth above, the Reporting Persons do not have any plans or proposals as of the date of this filing which relate to or would result in any of the actions enumerated in Item 4 of the instructions to Schedule 13D. As of the date hereof, each of Vladimir Galkin and Angelica Galkin may be deemed to beneficially own 796,007 shares of Common Stock, representing approximately 16.0% of the issued and outstanding shares of Common Stock of Issuer. The foregoing beneficial ownership percentages reported in this Item 5 are based on 5,350,183 shares of the Issuer's Common Stock issued and outstanding as of November 6, 2025, based on information reported by the Issuer in the Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, and filed with the Securities and Exchange Commission (the SEC) on November 13, 2025. See Rows 7-10 of the cover page for information regarding the power to vote or direct the vote and the power to dispose or direct the disposition of the shares of Common Stock by each of the Reporting Persons. All the transactions involving shares of Common Stock effected during the past sixty (60) days by any of the Reporting Persons, which were all in the open market, are set forth in Schedule A, and are incorporated herein by reference. Except as otherwise noted below, all such transactions were purchases and sales of shares of Common Stock effected in the open market, and the table includes commissions paid in per share prices. Not Applicable No person other than a Reporting Person has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, Common Stock beneficially owned by the Reporting Persons. 1. Schedule A 2. Joint Filing Agreement Galkin Vladimir Vladimir Galkin 12/26/2025 Galkin Angelica Angelica Galkin 12/26/2025